Annual sales moved from KRW 846.5 billion in 2022 to KRW 828.9 billion in 2023 (down 2.1% year on year), then rose to KRW 897.1 billion in 2024 (up 8.2%) and KRW 1.06 trillion in 2025 (up 18.5%), growing for two consecutive years from 2024 to 2025.
Operating profit went from KRW 52.5 billion in 2022 to KRW 65.9 billion in 2023 (up 25.5%), KRW 88.2 billion in 2024 (up 33.8%) and KRW 110.9 billion in 2025 (up 25.7%), rising for three consecutive years from 2023 to 2025, while the operating margin widened from 6.2% in 2022 to 10.4% in 2025.
Profit attributable to controlling shareholders rose from KRW 38.1 billion in 2022 to KRW 75.7 billion in 2025, and net income including non-controlling interests was disclosed at the same amounts for each year.
Operating profit grew faster than sales in several years, which points to a larger contribution from higher-margin Keycap prescriptions and overseas royalties.
The debt-to-equity ratio, however, rose to 57.9% in 2025 from 51.0% in 2024, with total liabilities of KRW 768.5 billion and total equity of KRW 1.33 trillion at year-end 2025. Operating cash flow grew from KRW 58.6 billion in 2022 to KRW 162 billion in 2025. The quarterly path diverged from the annual trend.
Sales rose from KRW 260.8 billion in 3Q25 to KRW 291.9 billion in 4Q25 (up 11.9% quarter on quarter) before falling to KRW 258.7 billion in 1Q26 (down 11.4%), then KRW 267.2 billion in 2Q26 (up 3.3%) and KRW 260.4 billion in 3Q26 (down 2.6%).
Operating profit peaked at KRW 40.1 billion in 4Q25 (up 55.0% quarter on quarter), then fell to KRW 33.2 billion, KRW 30 billion and KRW 26 billion across 1Q26 to 3Q26, declining for three consecutive quarters. Operating profit was up 30.8% year on year in 1Q26 and up 0.6% in 3Q26.
Profit attributable to controlling shareholders fell to KRW 13.7 billion in 2Q26 (down 47.3% quarter on quarter) and recovered to KRW 19.6 billion in 3Q26 (up 43.3%). The last four quarters, from 4Q25 to 3Q26, total KRW 86.9 billion in profit attributable to controlling shareholders.